Glaxo's Tykerb Cuts Breast Cancer Stem Cells, Slows Spread

Bloomberg.com: : "GlaxoSmithKline Plc's Tykerb reduced breast cancer stem cells in one study, helping eliminate the disease in some patients. In a second trial, it shrank tumors that had spread to the brain when used with another treatment.
The two reports, presented yesterday at the San Antonio Breast Cancer Symposium in Texas, may help Glaxo, the world's second-biggest drugmaker, increase its share of the $47 billion global cancer market dominated by Roche Holding AG and Genentech Inc. Tykerb, approved in the U.S. in March and in Europe on Dec. 14, works in patients with the HER-2 gene, which makes the disease more aggressive in as many as 30 percent of patients."